Immunology News and Research

Latest Immunology News and Research

Exposure to mold during infancy linked to asthma development during childhood

In the United States, one in 10 children suffers from asthma but the potential environmental factors contributing to the disease are not well known. Cincinnati-based researchers now report new evidence that exposure to three types of mold during infancy may have a direct link to asthma development during childhood.

3 Aug 2012

Allergy alerts in patient records help improve clinical practice

Allergy alerts in patient records have the potential to significantly improve clinical practice, say Spanish researchers.

3 Aug 2012

B-cell substances may play a role in MS progression

Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment.

2 Aug 2012

Freiburg scientist receives ERC Starting Grant for NutrImmune project

The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe's most prestigious grants for young investigators.

1 Aug 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.

31 Jul 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

OX40 molecule responsible for airway inflammation in the lungs

A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

In a quest to make safer and more effective vaccines, scientists at the Biodesign Institute- at Arizona State University have turned to a promising field called DNA nanotechnology to make an entirely new class of synthetic vaccines.

27 Jul 2012

Lymphoma drug dislodges hidden virus in HIV patients

Researchers from the University of North Carolina at Chapel Hill have published pioneering research showing that a drug used to treat certain types of lymphoma was able to dislodge hidden virus in patients receiving treatment for HIV.

27 Jul 2012

Skin microbiota may help protect the body from infection

A research team at the National Institutes of Health has found that bacteria that normally live in the skin may help protect the body from infection. As the largest organ of the body, the skin represents a major site of interaction with microbes in the environment.

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Study shows potential for histone deacetylase inhibitors to eradicate latent HIV infection

Merck, known as MSD outside the United States and Canada, announced today the publication of a study in the July 26 issue of the leading scientific journal Nature that provided early evidence for the use of a drug to dislodge reservoirs of hidden virus in patients receiving treatment for HIV, the virus that causes AIDS.

26 Jul 2012

How an opportunistic fungal pathogen knows when to attack

The opportunistic fungal pathogen Candida albicans inconspicuously lives in our bodies until it senses that we are weak, when it quickly adapts to go on the offensive. The fungus, known for causing yeast and other minor infections, also causes a sometimes-fatal infection known as candidemia in immunocompromised patients. An in vivo study, published in mBio, demonstrates how C. albicans can distinguish between a healthy and an unhealthy host and alter its physiology to attack.

25 Jul 2012

Children missing out on in battle against TB

The number of children diagnosed with tuberculosis only represents the tip of the iceberg, according to the University of Sydney’s Associate Professor Ben Marais, a specialist in childhood tuberculosis writing in the latest issue of The New England Journal of Medicine.

25 Jul 2012

WASC accredits Cedars-Sinai PhD program in biomedical sciences and translational medicine

The Graduate Program in Biomedical Sciences and Translational Medicine at Cedars-Sinai has been accredited by the Western Association of Schools and Colleges, an affirmation that the PhD-awarding educational effort meets the most rigorous standards of higher learning.

25 Jul 2012